What question did this study set out to answer?

To explore how cannabidiol (CBD) modulates the NLRP3 inflammasome and assess its therapeutic implications.

June 14, 2026Journal of Holistic Integrative Pharmacy1 citationsOpen Access

Cannabidiol as a modulator of NLRP3 inflammasome: Mechanistic insights and therapeutic potential

DJDharshini JaisankarSaveetha University JNJ. NandhiniSaveetha University

Key Points

To explore how cannabidiol (CBD) modulates the NLRP3 inflammasome and assess its therapeutic implications.
Synthesis of mechanistic and translational evidence regarding CBD's modulation of the NLRP3 inflammasome.
Review of interconnected pathways impacted by CBD, including NF-kB suppression and ionic flux regulation.
Discussion of preclinical models related to neuroinflammation, colitis, and metabolic dysfunction.
CBD reduces caspase-1 activation and decreases IL-1β and IL-18 release in preclinical models.
CBD's mechanisms include suppression of NF-κB activation and attenuation of oxidative stress.
Clinical translation is limited due to poor oral bioavailability and complex pharmacokinetics.

Abstract

Dysregulated activation of the NLRP3 inflammasome is a central driver of chronic inflammatory, neurodegenerative, metabolic, and autoimmune diseases, contributing significantly to the global burden of disease and reduced quality of life. Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from Cannabis sativa , has emerged as a promising complementary and integrative therapeutic agent due to its broad anti-inflammatory and immunomodulatory properties. This narrative review synthesizes current mechanistic and translational evidence demonstrating that CBD modulates NLRP3 inflammasome activity through multiple interconnected pathways. These include suppression of NF- κ B–mediated priming, attenuation of mitochondrial dysfunction and reactive oxygen species generation, regulation of ionic fluxes, and enhancement of autophagic clearance of inflammasome activators. Collectively, these actions lead to reduced caspase-1 activation and decreased release of interleukin-1 β and interleukin-18, conferring protective effects in preclinical models of neuroinflammation, colitis, metabolic dysfunction, and organ injury. Despite robust preclinical support, clinical translation of CBD remains constrained by poor oral bioavailability, extensive first-pass metabolism, and formulation-dependent pharmacokinetics highlighting the need for innovative, affordable, and accessible pharmaceutical technologies. Emerging pharmaceutical strategies, including nano-delivery systems and advanced formulations, offer potential solutions to these limitations. Viewed through a systems-oriented pharmacological framework, CBD represents a plant-based, multi-target modulator capable of regulating complex inflammatory networks rather than single molecular targets. While existing evidence supports its therapeutic promise, biomarker-driven clinical trials are essential to establish its efficacy and clinical relevance in inflammasome-driven diseases.

AI से पूछें

Bookmark

View Full Paper